No Data
No Data
Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
JPMorgan Becomes Substantial Holder in Mesoblast
Mesoblast Seeks to Extend Ryoncil Label to Adults With Graft Versus Host Disease; Shares Rise 3%
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor in Ischemic Heart Failure and Label Extension for Ryoncil in Adults With GvHD
Mesoblast (ASX:MSB) Gains 15% In One Week With US FDA Orphan-Drug Approval
Vanguard Group Acquires Substantial Stake in Mesoblast Limited
stderr : meso is getting ahead of msb, especially here. Just crazy people on moomoo?